NPSP
NPS Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Feb. 25, 2015, 3:28 PM
    • Shire plc (SHPG +3%) completes its acquisition on NPS Pharmaceuticals (NASDAQ:NPSP). As of midnight, February 20, 81.7% of NPSP shares had been tendered.
    | Feb. 25, 2015, 3:28 PM | 1 Comment
  • Feb. 19, 2015, 7:29 AM
    • NPS Pharmaceuticals (NPSP) Q4 results: Revenues: $66.7M (+22.4%); Operating Income: $0.9M (-91.5%); Net Loss: ($2M) (-125.6%); Loss Per Share: ($0.02) (-128.6%).
    • FY2014 results: Revenues: $224.1M (+44.0%); COGS: $14.6M (+305.6%); R&D Expense: $90.1M (+5.5%); SG&A: $114.3M (+67.8%); Operating Income: $5.1M (+440.0%); Net Loss: ($8.7M) (+35.6%); Loss Per Share: ($0.08) (+42.9%); Quick Assets: $164.2M (-9.0%); CF Ops: ($16.7M) (-31.3%).
    • No guidance given.
    | Feb. 19, 2015, 7:29 AM
  • Feb. 19, 2015, 6:24 AM
    • NPS Pharmaceuticals (NASDAQ:NPSP): Q4 EPS of -$0.02 misses by $0.08.
    • Revenue of $66.69M (+22.5% Y/Y) misses by $2.41M.
    | Feb. 19, 2015, 6:24 AM
  • Jan. 24, 2015, 9:45 PM
    • The FDA approves NPS Pharmaceuticals' (NASDAQ:NPSP) Orphan Drug-designated Natpara (parathyroid hormone) to control hypocalcemia (low blood calcium) in patients with hypoparathyroidism, a rare disease that affects ~60K people in the U.S.
    • Natpara will now enjoy a seven-year period of market exclusivity for this indication as stipulated under Orphan Drug status.
    • Previously: PDUFA approaches for NPS Pharma's Natpara (Jan. 22)
    | Jan. 24, 2015, 9:45 PM | 7 Comments
  • Jan. 22, 2015, 1:32 PM
    • The PDUFA date for the FDA's review of NPS Pharmaceuticals' (NPSP +0.2%) Biologics License Application (BLA) for Natpara (rhPTH[1-84]) for the treatment of hypoparathyroidism is January 24. Since this is Saturday, the agency may report its decision tomorrow.
    • Approval is not certainty, though. The Ad Comm vote supporting approval was a slim 8 - 5 and the FDA extended its decision deadline three months in order review a major amendment to the BLA.
    • Previously: FDA extends Natpara PDUFA date (Oct. 23, 2014)
    • Previously: Positive Ad Comm vote for Natpara (Sept. 12, 2014)
    | Jan. 22, 2015, 1:32 PM | 3 Comments
  • Jan. 12, 2015, 9:14 AM
    | Jan. 12, 2015, 9:14 AM
  • Jan. 12, 2015, 1:50 AM
    • Shire (NASDAQ:SHPG) is buying NPS Pharmaceuticals (NASDAQ:NPSP), a maker of treatments for rare diseases, for $5.2B ($46 per share), a 51% premium to its share price on December 16, before rumors of the deal first surfaced.
    • The all-cash acquisition comes just three months after Shire’s proposed $54B sale to AbbVie (NYSE:ABBV) collapsed as a consequence of U.S. government efforts to limit tax-inversions. Shire received a $1.6B breakup fee after AbbVie walked away.
    • Previously: NPS Pharma up 20% on takeover buzz (Dec. 17 2014)
    | Jan. 12, 2015, 1:50 AM | 1 Comment
  • Jan. 6, 2015, 3:52 PM
    • NPS Pharmaceuticals (NPSP +7.6%) moves up on a 2.5x surge in volume. Investors' interest has been stoked after the Wall Street Journal reported that Goldman Sachs was putting feelers out about a possible acquisition. Shire plc is one candidate in light of its failed marriage with AbbVie.
    • Separately, the extended PDUFA date for the FDA's review of the company's BLA for Natpara for the treatment of hypoparathyroidism is January 24. Since this is a Saturday, the agency may issue its decision on Friday the 23rd. On September 12, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 8-5 in favor of approval.
    • Previously: FDA extends Natpara PDUFA date (Oct. 23, 2014)
    • Previously: Positive Ad Comm vote for Natpara (Sept. 12, 2014)
    | Jan. 6, 2015, 3:52 PM
  • Dec. 17, 2014, 11:21 AM
    • NPS Pharmaceuticals (NPSP +21.3%) jumps on increased volume in response to market chatter that Shire plc (SHPG +2.5%) is mulling a bid for the rare disease therapeutics developer.
    | Dec. 17, 2014, 11:21 AM | 2 Comments
  • Nov. 11, 2014, 10:58 AM
    • NPS Pharmaceuticals (NPSP +8.1%) Q3 results: Revenues: $57.2M (+45.9%); COGS: $3.2M (+190.9%); R&D Expense: $24.5M (+30.3%); SG&A: $28.1M (+59.7%); Operating Income: $1.4M (-22.2%); Net Loss: ($2.1M) (-90.9%); Loss Per Share: ($0.02) (-100.0%); Quick Assets: $169.3M (-6.2%).
    • 2014 Guidance: Sales: $100M from $100M - 110M; operating expenses: $185M - 195M from $180M - 200M.
    | Nov. 11, 2014, 10:58 AM
  • Nov. 10, 2014, 4:08 PM
    • NPS Pharmaceuticals (NASDAQ:NPSP): Q3 EPS of -$0.02 misses by $0.04.
    • Revenue of $57.2M (+45.9% Y/Y) misses by $2.55M.
    • Shares -4.7%.
    | Nov. 10, 2014, 4:08 PM
  • Nov. 9, 2014, 5:35 PM
  • Nov. 3, 2014, 10:00 AM
    • NPS Pharmaceuticals (NPSP +0.7%) will report Q3 results on November 10 after the close. The conference call will begin at 4:30 pm ET.
    • Consensus view is EPS of $0.01 on revenues of $59.5M.
    | Nov. 3, 2014, 10:00 AM
  • Oct. 23, 2014, 6:25 PM
    • Citing the need for more time to fully review a major amendment to the BLA, the FDA extends the PDUFA date for NPS Pharmaceuticals' (NPSP +5.1%) Natpara from October 24, 2014 to January 24, 2015. It also requested a Risk Evaluation and Mitigation Strategy (REMS) for the product. The company expects to finalize the REMS prior to January 24.
    | Oct. 23, 2014, 6:25 PM | 2 Comments
  • Oct. 21, 2014, 12:29 PM
    • The PDUFA date for the FDA's review of NPS Pharmaceuticals' (NPSP +0.1%) BLA for Natpara for the treatment of hypoparathyroidism is October 24.
    • Last month, the Endocrinologic and Metabolic Drugs Advisory Committee voted 8 - 5 in favor of approval.
    | Oct. 21, 2014, 12:29 PM
  • Oct. 19, 2014, 9:49 AM
    • Shire (NASDAQ:SHPG) may look to acquire an American rival after AbbVie pulled its proposed $55B takeover.
    • Possible targets include rare diseases specialist NPS Pharma (NASDAQ:NPSP) and Cubist Pharma (NASDAQ:CBST), which makes a treatment for superbug MRSA.
    • Source: Sunday Times
    | Oct. 19, 2014, 9:49 AM | 2 Comments